Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic ...

Vertex said on Tuesday that its next-generation drug gained European Commission approval for treating cystic fibrosis, a rare ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.

Vertex Pharmaceuticals' leap into the Russell 1000 Index marks its transformation from growth-focused biotech to blue-chip ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals got a fresh boost of confidence from H.C. Wainwright, which reaffirmed its Buy rating after the ADA ...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their ...

In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and ...